Kære HelpLine: Navigerer på rejser i løbet af ferien
Dear HelpLine, I am thinking of traveling to see family this year for the holidays, but this would be the first time taking my wife since she was diagnosed with FTD 2 years ago. Is there anything you can share with me about traveling with someone with FTD? For many people, the holiday season is…
Læs mereEn samtale med Alectors vicepræsident for klinisk udvikling
Earlier this year, the biopharmaceutical company Alector announced that the U.S. Food and Drug Administration (FDA) had granted a “breakthrough therapy designation” to latozinemab, the company’s investigational drug designed to address FTD caused by a variant in the GRN gene. The special designation enables expedited regulatory review of therapies intended to treat serious conditions. A…
Læs mereVesper Bio annoncerer vellykket afslutning af fase 1-undersøgelse for potentielt sygdomsmodificerende behandling af FTD-GRN
Biotechnology company Vesper Bio announced in early September that the phase 1 clinical trial for its potentially disease-modifying treatment for FTD-GRN has successfully concluded. The company noted data from the trial demonstrated excellent safety and tolerability of the orally administered drug VES001. In FTD caused by an inherited GRN mutation, the production of the essential…
Læs mere24. november 2024: In-Person Meet & Greet i Manchester, NH
Join and learn from others who understand the FTD journey at this in-person AFTD Meet & Greet event, hosted by AFTD Ambassador Shirley Gordon and Kevin Rhodes, co-chair of the AFTD Persons with FTD Advisory Council. The event will take place from 7:30 a.m. – 12:00 p.m. on November 24 at St. Catherine of Siena…
Læs mereIn-Person Meet & Greet i Manchester, NH
Join and learn from others who understand the FTD journey at this in-person AFTD Meet & Greet event, hosted by AFTD Ambassador Shirley Gordon and Kevin Rhodes, co-chair of the AFTD Persons with FTD Advisory Council. RSVP for this event by emailing sgordon@theaftd.org. To learn more, download this flyer.
Læs mereOhio Hybrid Caregiver frokost og lær: Frontotemporal demens
Tag en frokost med og slutt dig til Judy Bearer, ambassadør for Association for Frontotemporal Degeneration, til denne frokost og lær begivenheden om frontotemporal degeneration (FTD), den mest almindelige årsag til demens hos voksne under 60 år (selvom den kan ramme voksne i alle aldre). Vi vil gennemgå mulige årsager og symptomer, finde lokale ressourcer og lære, hvordan...
Læs mereAFTD-webinar: Diagnosticering af primær progressiv afasi
With primary progressive aphasia (PPA), problems with language and communication typically deteriorate gradually over time. Initial symptoms are sometimes attributed to anxiety or stress until the ongoing symptoms become disruptive enough to prompt further assessment by a specialist. This webinar is intended for clinicians to support early detection and accurate diagnosis of PPA. Learners will…
Læs mereFortæl dine lovgivere: Genautoriser finansiering til loven om ældre amerikanere
You may think that because frontotemporal degeneration strikes many people in the middle of their life, that the Older Americans Act may not apply to you. But the OAA provides funding for services for adult family members and other adults who care for individuals with Alzheimer’s disease and related disorders in their home, regardless of…
Læs mereAdvancing Hope: AFTD er vært for 2024 FTD Research Roundtable Meeting
The FTD Research Roundtable is an annual program designed to accelerate FTD drug development by convening various scientific stakeholders to identify common challenges and advance solutions for FTD clinical trials. Biopharmaceutical companies currently conducting FTD pre-clinical and clinical trials are invited to join the FTD Research Roundtable, and in 2024, we were thrilled to have…
Læs mereAC Immune and Life Molecular Imaging annoncerer FDA Fast Track-betegnelse for Tau PET Tracer
Swiss biopharmaceutical company AC Immune announced in late August that its partner, German biopharmaceutical company Life Molecular Imaging (LMI), received a Fast Track Designation from the US Food and Drug Administration (FDA) for a Tau PET tracer. PET, or positron emission tomography, is a form of medical imaging that uses a radioactive tracer to visualize…
Læs mere
Danish 
English 
Spanish (Mexico) 
French 
German 
Swedish 
Portuguese 
Italian 
Dutch 
Polish 
Spanish (Spain)